Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Glycine-N-acyltransferase like 1 (GLYATL1) is a mitochondrial enzyme belonging to the acyltransferase family, closely related to glycine N-acyltransferase (GLYAT). It catalyzes the transfer of acyl groups from acyl-CoA donors (such as phenylacetyl-CoA) to amino acids like glutamine or glycine, forming conjugated amino acid derivatives that are important in the metabolism and detoxification of endogenous and xenobiotic compounds. The protein is mostly found in human tissues such as the liver and is involved in phase II metabolism, which facilitates the excretion of potentially harmful compounds. While GLYATL1 participates in essential metabolic processes and acts as an enzyme, there is little evidence to date that it is directly implicated as a driver in major disease pathways; it is, however, associated with glutamine metabolic processes and may be related to select metabolic disorders[2][3][4].
Enzyme catalyzes transfer of an acyl group from acyl-CoA (such as phenylacetyl-CoA) to an amino acid (such as glutamine or glycine)[2][4]. Essential for conjugation of certain carboxylic acids, aiding in detoxification and excretion.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glycine-N-acyltransferase like 1 (GLYATL1).